Scientists Discover Key Protein That Drives Liver Scarring and Potential Treatment Target
New research reveals how SREBP2 protein triggers liver fibrosis through metabolic changes, offering hope for treating liver disease.
Summary
Scientists discovered that a protein called SREBP2 plays a crucial role in liver scarring (fibrosis) by controlling how liver cells produce energy molecules. When researchers blocked SREBP2 or its target enzyme ACSS2 in mice, liver scarring was significantly reduced. The study found that SREBP2 activates ACSS2, which then produces acetyl-CoA molecules that modify DNA packaging, turning on genes that cause liver scarring. Importantly, a small-molecule drug that blocks ACSS2 also prevented liver fibrosis in animal models. This pathway was confirmed in human liver samples from cirrhosis patients, suggesting potential new treatments for liver disease.
Detailed Summary
Liver fibrosis, the scarring that leads to cirrhosis and liver cancer, affects millions worldwide and currently has limited treatment options. This groundbreaking research identifies a new molecular pathway that could be targeted to prevent or reverse liver damage.
Researchers studied how hepatic stellate cells transform into scar-producing cells during liver injury. Using advanced genetic techniques, they deleted specific proteins in mouse liver cells and tracked the effects on fibrosis development. They combined RNA sequencing with chromatin analysis to map how genes are regulated during this process.
The team discovered that SREBP2, a protein that normally regulates cholesterol metabolism, directly controls ACSS2 enzyme production. ACSS2 then generates acetyl-CoA molecules that modify histones—proteins that package DNA—leading to activation of fibrosis-promoting genes. When either SREBP2 or ACSS2 was removed from liver cells, mice developed significantly less scarring after injury.
Most importantly, treating mice with a small-molecule ACSS2 inhibitor reduced liver fibrosis, demonstrating therapeutic potential. The researchers validated their findings in human liver biopsies from cirrhosis patients, confirming this pathway's relevance to human disease.
For longevity and health optimization, this research suggests that metabolic interventions targeting acetyl-CoA production might protect liver function. Since liver health is crucial for detoxification, metabolism, and overall longevity, preventing fibrosis could significantly impact healthspan. However, these findings are preliminary and require clinical trials to determine safety and efficacy in humans.
Key Findings
- SREBP2 protein deletion in liver cells reduced fibrosis by 60-70% in mouse models
- ACSS2 enzyme serves as key link between metabolism and gene activation in liver scarring
- Small-molecule ACSS2 inhibitor successfully prevented liver fibrosis in animal studies
- SREBP2-ACSS2 pathway confirmed active in human cirrhosis patient samples
- Blocking acetyl-CoA production prevents activation of scar-forming genes
Methodology
Researchers used genetically modified mice with cell-specific protein deletions, combined RNA sequencing with chromatin mapping, and validated findings in human liver biopsy samples from cirrhosis patients. Multiple mouse models of liver injury were employed to test therapeutic interventions.
Study Limitations
Study conducted primarily in mouse models with limited human validation. Long-term safety and efficacy of ACSS2 inhibition in humans remains unknown. Effects on other metabolic processes requiring acetyl-CoA production need further investigation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.